TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30037432

Group type: EXPERIMENTAL
Intervention: Ustekinumab (UST)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Tumor necrosis factor inhibitors (TNFi)
Number of subjects: 47
Study: 29036250

Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.25% topical spray
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% spray
Number of subjects: 32
Study: 25476537

Group type: EXPERIMENTAL
Intervention: Vorinostat (400 mg orally daily, days 1-3 of every 7-d period) with carboplatin (AUC 2, weekly) and nab-paclitaxel (100 mg/m2 weekly)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo with carboplatin (AUC 2, weekly) and nab-paclitaxel (100 mg/m2 weekly)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both interventions (vorinostat and placebo)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Change in SUL(max) on (18)F-FDG PET
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Baseline and change in Ki-67
Number of subjects: 62
Study: 23117253

Group type: EXPERIMENTAL
Intervention: LORS-Enabled Dialogue (LED) intervention
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 21363973

Group type: EXPERIMENTAL
Intervention: HIV infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hookworm infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S. haematobium infection
Number of subjects: 0
Study: 18645542

Group type: EXPERIMENTAL
Intervention: J‐Tip jet injection of 1% buffered lidocaine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Topical 4% ELA‐Max
Number of subjects: 70
Study: 16585868

Group type: EXPERIMENTAL
Intervention: Weekly docetaxel and cisplatin (25 mg/m cisplatin and 35 mg/m docetaxel once a week for 3 weeks followed by 1 week without treatment)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Weekly docetaxel and cisplatin
Number of subjects: 21
Study: 12650633

Group type: EXPERIMENTAL
Intervention: Levonorgestrel implants
Number of subjects: 16000

Group type: COMPARATOR
Intervention: Jadelle
Number of subjects: 16000
Study: 11098103

Group type: EXPERIMENTAL
Intervention: Continuous infusion of morphine (targeted concentration of 20 ng/ml)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Intermittent bolus doses of morphine
Number of subjects: 83
Study: 1300518

Group type: EXPERIMENTAL
Intervention: Discolored lenses (amber lens discoloration achieved using human‐worn 55% water hydrophilic contact lenses heated in a 1% potassium sorbate, low pH saline solution)
Number of subjects: 15
Study: 3895254

Group type: COMPARATOR
Intervention: Lofepramine (140 mg and 210 mg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Amitriptyline (100 mg and 150 mg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 5
Study: 31315118

Group type: EXPERIMENTAL
Intervention: Normal weight participants dividing monetary rewards in the dictator game
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Normal weight participants with stronger explicit antifat attitudes
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Implicit attitudes toward people with obesity
Number of subjects: 168
Study: 29725983

Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg every 2 weeks
Number of subjects: 1902

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 1902

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1902
Study: 27801404

Group type: EXPERIMENTAL
Intervention: Biological feedback (BFB) technique
Number of subjects: 337

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 337
Study: 25493596

Group type: COMPARATOR
Intervention: No chemoprevention
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Monthly dihydroartemisinin-piperaquine
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Daily trimethoprim-sulfamethoxazole
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Monthly sulfadoxine-pyrimethamine
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Number of subjects: 186
Study: 22314936

Group type: EXPERIMENTAL
Intervention: Screening for fracture risk using the FRAX algorithm and DXA assessment.
Number of subjects: 11580

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 11580
Study: 20379614

Group type: EXPERIMENTAL
Intervention: 21 mg NRT
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: 42 mg NRT
Number of subjects: 479

Group type: COMPARATOR
Intervention: NRT (both doses)
Number of subjects: 479
Study: 18339044

Group type: EXPERIMENTAL
Intervention: +2DS blur over the dominant eye
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: +2DS blur over the non-dominant eye
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Dominant eye occluded
Number of subjects: 14

Group type: COMPARATOR
Intervention: Binocular vision
Number of subjects: 14
Study: 15844708

Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a plus ribavirin (180 microg peg‐interferon alpha‐2a + 800-1000 mg/day ribavirin)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Ribavirin and amantadine (800-1000 mg/day ribavirin + 200 mg/day amantadine)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a plus mycophenolate mofetil (180 microg peg‐interferon alpha‐2a + 2 g/day mycophenolate mofetil)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Amantadine (200 mg/day)
Number of subjects: 124
Study: 14501100

Group type: EXPERIMENTAL
Intervention: strategy group (received training on methods for remembering picture groupings)
Number of subjects: 24

Group type: COMPARATOR
Intervention: control group (received no training)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: strategy group
Number of subjects: 24
Study: 11829803

Group type: EXPERIMENTAL
Intervention: Short veno-venous hemofiltration (SVVH, 4hr)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-hemofiltration group (NHF)
Number of subjects: 20
Study: 8644661

Group type: EXPERIMENTAL
Intervention: Felodipine ER 2.5 to 5 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril and loop diuretics with or without digoxin
Number of subjects: 0
Study: 1728688

Group type: EXPERIMENTAL
Intervention: Cefuroxime (1.5 gm before operation and 750 mg every 3 hours during operation)
Number of subjects: 559

Group type: COMPARATOR
Intervention: Cefazolin (1 gm before operation and 500 mg every 4 hours during operation)
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 559

Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 559
Study: 6741802

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 to 50 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Hydralazine (5 to 30 mg)
Number of subjects: 15
Study: 31521257

Group type: EXPERIMENTAL
Intervention: Inferior vena cava (IVC) filters
Number of subjects: 0

Group type: COMPARATOR
Intervention: IVC filters
Number of subjects: 0
Study: 30071416

Group type: EXPERIMENTAL
Intervention: dTMS combined with SSRIs
Number of subjects: 34

Group type: COMPARATOR
Intervention: sham dTMS
Number of subjects: 34
Study: 27310980

Group type: EXPERIMENTAL
Intervention: He electroacupuncture
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Shu-Mu electroacupuncture
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: He-Shu-Mu electroacupuncture
Number of subjects: 448

Group type: COMPARATOR
Intervention: Loperamide
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (all groups combined)
Number of subjects: 448
Study: 24586404

Group type: EXPERIMENTAL
Intervention: Morning-type group in the morning session
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morning-type group in the evening session
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evening-type group in the morning session
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evening-type group in the evening session
Number of subjects: 0
Study: 22925169

Group type: EXPERIMENTAL
Intervention: Portion control diet
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Low energy density diet
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Low glycemic index diet
Number of subjects: 157

Group type: COMPARATOR
Intervention: All groups combined
Number of subjects: 157
Study: 20395917

Group type: EXPERIMENTAL
Intervention: Sub-conjunctival injection of dexamethasone and gentamicin combination (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 5% povidone-iodine drop (Group B)
Number of subjects: 60
Study: 17504616

Group type: EXPERIMENTAL
Intervention: Physio-psychological treatment
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Drug treatment (DDAVP tablets)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Combined treatment (physio-psychological + drug treatment)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 178
Study: 16521533

Group type: EXPERIMENTAL
Intervention: Sonographic examination in preterm neonates
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group of 31 children from term deliveries
Number of subjects: 143
Study: 11961326

Group type: EXPERIMENTAL
Intervention: Remineralization without fluoride (Group B)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Remineralization with 1 ppm fluoride (Group C)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Natural incipient lesions (Group D)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 4
Study: 10409589

Group type: EXPERIMENTAL
Intervention: Melatonin (2 x 1-mg capsules)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (2 capsules)
Number of subjects: 9
Study: 7556743

Group type: EXPERIMENTAL
Intervention: Tropicamide Novel Ophthalmic Delivery System (NODS) and guttae phenylephrine 10% applied once, 2 hours before surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard pre-operative regime of guttae cyclopentolate 1% and guttae phenylephrine 10% used four times before surgery
Number of subjects: 0
Study: 2062626

Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb strain measles vaccine (high dose)
Number of subjects: 2097

Group type: COMPARATOR
Intervention: Schwarz strain measles vaccine (control)
Number of subjects: 2097
Study: 6628523

Group type: EXPERIMENTAL
Intervention: Oral pindolol
Number of subjects: 6

Group type: COMPARATOR
Intervention: i.v. pindolol
Number of subjects: 6
Study: 31063192

Group type: EXPERIMENTAL
Intervention: Immediate initiation of antiretroviral therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deferred initiation of antiretroviral therapy
Number of subjects: 0
Study: 30024203

Group type: EXPERIMENTAL
Intervention: Everyday Matters program
Number of subjects: 31

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 31
Study: 27103111

Group type: EXPERIMENTAL
Intervention: Preventive induction of labor at 37-39 weeks
Number of subjects: 200000

Group type: COMPARATOR
Intervention: Ongoing pregnancy (expectant management)
Number of subjects: 200000
Study: 25469046

Group type: EXPERIMENTAL
Intervention: Xiaoyao pill
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 22302316

Group type: EXPERIMENTAL
Intervention: Intra-articular betamethasone injections (28 mg, up to four swollen joints/visit)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Intra-articular betamethasone injections
Number of subjects: 160
Study: 19398575

Group type: EXPERIMENTAL
Intervention: Epirubicin/platinum/fluoropyrimidine combination chemotherapy (ECF, ECX, EOF, EOX) with 1 mg of warfarin for thromboprophylaxis
Number of subjects: 964

Group type: COMPARATOR
Intervention: Epirubicin/platinum/fluoropyrimidine combination chemotherapy (EOF/EOX)
Number of subjects: 964

Group type: COMPARATOR
Intervention: Epirubicin/platinum/fluoropyrimidine combination chemotherapy (F group)
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Epirubicin/platinum/fluoropyrimidine combination chemotherapy (ECF/EOF arms)
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Epirubicin/platinum/fluoropyrimidine combination chemotherapy
Number of subjects: 964
Study: 17234730

Group type: EXPERIMENTAL
Intervention: High-dose RRR-alpha-tocopherol (1200 IU/day for 2 years)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 16314551

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Sleep hygiene (SH) instructions
Number of subjects: 47

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 47
Study: 12494125

Group type: EXPERIMENTAL
Intervention: Heart fatty acid binding protein (FABP)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Troponin I (TnI)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Creatine kinase (CK)
Number of subjects: 57
Study: 10219658

Group type: EXPERIMENTAL
Intervention: 1% HA in phosphate buffered saline (PBS)
Number of subjects: 26

Group type: COMPARATOR
Intervention: 0.01% HA in PBS (Control)
Number of subjects: 26
Study: 8580883

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 2131864

Group type: EXPERIMENTAL
Intervention: Isoflurane (ISO group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP group)
Number of subjects: 20
Study: 6996618

Group type: EXPERIMENTAL
Intervention: Topical application of 0.05% fluocinonide in an adhesive base
Number of subjects: 89
Study: 30535396

Group type: EXPERIMENTAL
Intervention: Group prenatal care (CenteringPregnancy model)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Traditional one-on-one prenatal care
Number of subjects: 129
Study: 28039583

Group type: EXPERIMENTAL
Intervention: 1 g D-chiro-inositol plus 400 mcg folic acid once daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: 400 mcg folic acid only once daily
Number of subjects: 26
Study: 25450134

Group type: EXPERIMENTAL
Intervention: Computer-assisted home exercise program
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conservative home-training following printed instructions
Number of subjects: 63
Study: 23750773

Group type: EXPERIMENTAL
Intervention: Coping plans made to deal with personal smoking related risk situations
Number of subjects: 563
Study: 22773240

Group type: EXPERIMENTAL
Intervention: Octreotide long-acting repeatable depot (OctLAR), maximum dose 40 mg, administered for 2 years (Year 1 and Year 2).
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Octreotide long-acting repeatable depot (OctLAR), administered for 2 years (Year 1 and Year 2).
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Octreotide long-acting repeatable depot (OctLAR), pooled analyses of all individuals who received OctLAR for 12 months.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo group (Year 1), crossed over to OctLAR in Year 2.
Number of subjects: 42
Study: 19682194

Group type: EXPERIMENTAL
Intervention: p.o. omeprazole 80 mg bolus followed by 40 mg every 12 h for 72 h
Number of subjects: 90

Group type: COMPARATOR
Intervention: i.v. omeprazole 80 mg followed by infusion 8 mg/h for 72 h
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: p.o. pantoprazole 80 mg bolus followed by 80 mg every 12 h for 72 h
Number of subjects: 90

Group type: COMPARATOR
Intervention: i.v. pantoprazole 80 mg followed by infusion 8 mg/h for 72 h
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: p.o. rabeprazole 80 mg bolus followed by 40 mg every 12 h for 72 h
Number of subjects: 90

Group type: COMPARATOR
Intervention: i.v. rabeprazole 80 mg followed by infusion 8 mg/h for 72 h
Number of subjects: 90

Group type: COMPARATOR
Intervention: No proton pump inhibitor treatment
Number of subjects: 90
Study: 17261396

Group type: EXPERIMENTAL
Intervention: Clopidogrel for 180 days
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Clopidogrel for 30 days
Number of subjects: 1004
Study: 15371861

Group type: EXPERIMENTAL
Intervention: Saline filled testicular prosthesis
Number of subjects: 149
Study: 11592359

Group type: EXPERIMENTAL
Intervention: 0.5 mg CII
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: COMPARATOR
Intervention: 0.05 mg CII
Number of subjects: 55

Group type: COMPARATOR
Intervention: 5 mg CII
Number of subjects: 55
Study: 10346406

Group type: EXPERIMENTAL
Intervention: Intravenous glucose (50 ml of 50% glucose)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intramuscular glucagon (1 mg)
Number of subjects: 14
Study: 7988951

Group type: EXPERIMENTAL
Intervention: Automated image analysis method for evaluating platelet interactions with ECM-coated coverslips
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard morphometric procedures
Number of subjects: 0
Study: 3183692

Group type: EXPERIMENTAL
Intervention: Temporary lacrimal duct occlusion
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham occlusion
Number of subjects: 11
Study: 4213814

Group type: EXPERIMENTAL
Intervention: Copper bearing device
Number of subjects: 155

Group type: COMPARATOR
Intervention: Conventional type device
Number of subjects: 155
Study: 31240722

Group type: EXPERIMENTAL
Intervention: NDP-led care
Number of subjects: 11281

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 11281

Group type: COMPARATOR
Intervention: Usual care plus
Number of subjects: 11281
Study: 28122530

Group type: EXPERIMENTAL
Intervention: VIA/VILI
Number of subjects: 3086

Group type: COMPARATOR
Intervention: TCT
Number of subjects: 3086

Group type: COMPARATOR
Intervention: HPV test
Number of subjects: 3086
Study: 25198401

Group type: EXPERIMENTAL
Intervention: Current perception threshold (CPT) measurement combined with stinging test using 50 μL 10% lactic acid
Number of subjects: 0
Study: 23975860

Group type: EXPERIMENTAL
Intervention: Conventional treatment plus medication education (access to information booklets and eight 30-min face-to-face counselling sessions over 4 weeks)
Number of subjects: 237

Group type: COMPARATOR
Intervention: No education (control group)
Number of subjects: 237
Study: 21964996

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (400/100 mg twice daily)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: atazanavir/ritonavir (300/100 mg once a day)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: efavirenz (600 mg once a day)
Number of subjects: 242
Study: 18638591

Group type: EXPERIMENTAL
Intervention: Semicompliant balloon (SC; Maverick(2))
Number of subjects: 301

Group type: COMPARATOR
Intervention: Noncompliant balloon (NC; Quantum)
Number of subjects: 301
Study: 15978714

Group type: EXPERIMENTAL
Intervention: Clearfil liner bond II (LB) with hybrid resin composite (Clearfil AP-X)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Single bond (SB) with hybrid resin composite (Clearfil AP-X)
Number of subjects: 72
Study: 12888226

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers, beta-blockers, spironolactone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recent heart failure guidelines (European Society of Cardiology and American College of Cardiology/American Heart Association)
Number of subjects: 0
Study: 11141388

Group type: EXPERIMENTAL
Intervention: Oral levofloxacin (LVF), 500 mg v.o. every 24 h
Number of subjects: 84

Group type: COMPARATOR
Intervention: Intravenous amoxicillin/clavulanate (AMX/CL), 1.02 g i.v. every 8 h
Number of subjects: 84

Group type: COMPARATOR
Intervention: Intravenous ceftriaxone (CTX), 1 g i.v. every 12 h
Number of subjects: 84
Study: 9099463

Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Triazolam (0.5 mg, twice the recommended dose)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 8442983

Group type: EXPERIMENTAL
Intervention: Fibrin glue application after surgery
Number of subjects: 114

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 114
Study: 3646716

Group type: EXPERIMENTAL
Intervention: Assertion training
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: First aid instruction
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Assertion/first aid
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control
Number of subjects: 92
Study: 30469333

Group type: EXPERIMENTAL
Intervention: Calorie restriction (n = 19)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (n = 13)
Number of subjects: 32
Study: 27211862

Group type: EXPERIMENTAL
Intervention: Aquatic resistance training
Number of subjects: 87

Group type: COMPARATOR
Intervention: Usual level of physical activity
Number of subjects: 87
Study: 24318654

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM)
Number of subjects: 240

Group type: COMPARATOR
Intervention: 1-day psychoeducation control group
Number of subjects: 240
Study: 22153774

Group type: EXPERIMENTAL
Intervention: IgE‐associated eczema
Number of subjects: 40

Group type: COMPARATOR
Intervention: Infants without allergic manifestation
Number of subjects: 40
Study: 20934833

Group type: EXPERIMENTAL
Intervention: Intervention pharmacies received weekly updates on EC, fliers with three key messages on EC, and information, education, and communication materials.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intervention pharmacies
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control pharmacies
Number of subjects: 17
Study: 18481319

Group type: EXPERIMENTAL
Intervention: Pre-operative inflammatory markers (CRP, IL-6, IGF-1)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Pre-operative IL-6 levels
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (patients who did not develop delirium)
Number of subjects: 68
Study: 16536247

Group type: EXPERIMENTAL
Intervention: Narcotic administration (as morphine equivalents)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Initial HCAT administration
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Subsequent HCAT administrations (postoperative days 1-5)
Number of subjects: 30
Study: 12935394

Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride (RLX) 60 mg daily for 12 months
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 11065084

Group type: EXPERIMENTAL
Intervention: Restriction of supplementary fluids for breast fed infants in the first week of life and avoidance of artificial teats and pacifiers
Number of subjects: 602